Best Momentum Stocks To Buy For February 13th

Comments
Loading...

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, February 13th:

Veracyte, Inc. VCYT: This diagnostics company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 20.4% over the last 60 days.

Veracyte, Inc. Price and Consensus

Veracyte, Inc. Price and Consensus

Veracyte, Inc. price-consensus-chart | Veracyte, Inc. Quote

Veracyte's shares gained 2.2% over the last three months compared with the S&P 500's advance of 1%. The company possesses a Momentum Score  of A.

Northern Trust Corporation NTRS: This wealth management company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.7% over the last 60 days.

Northern Trust's shares gained 3.05% over the past three months compared with the S&P 500's advance of 1%. The company possesses a Momentum Score of A.

 

See the full list of top ranked stocks here

 

Learn more about the Momentum score and how it is calculated here.

 

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Northern Trust Corporation NTRS: Free Stock Analysis Report
 
Veracyte, Inc. VCYT: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Overview Rating:
Good
62.5%
Technicals Analysis
66
0100
Financials Analysis
60
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In: